← Leaderboards
Helen Cecilia Fox
Yale University
$6,429,961
Attributed
$9,033,987
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,033,987 · 9
By mechanism
R01$5,831,386 · 3
R21$835,192 · 2
R61$812,516 · 1
K01$771,657 · 1
K02$643,465 · 1
R03$139,771 · 1
Top collaborators
- Rajita Sinha10 shared
- Suchismita Ray2 shared
Most similar at Yale University
Same institution · by research overlap
- Rajita Sinha$53,551,446
- Ismene L Petrakis$10,363,765
- Thomas James Melia$10,640,079
- Marina R. Picciotto$36,006,961
- Linda Carol Mayes$17,529,015
Others in their field
Top investigators on “Craving”
- Rajita Sinha · Yale University$32,214,060
- Barbara J Mason · Scripps Research Institute, The$21,503,310
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$21,234,516
- Kathleen Theresa Brady · Medical University Of South Carolina$20,546,089
- Dorothy K Hatsukami · University Of Minnesota Twin Cities$20,264,889
- Andrew S Huhn · Johns Hopkins University$19,514,484
Research focus
CravingStressNegative MoodAnxietyPharmaceutical PreparationsRelapseExposure ToImageryMoodsAlcohol CravingPlacebosAlcoholsAlcohol ConsumptionProblem DrinkerHydrocortisoneGenderNorepinephrineDrinkingBaseComorbidityAlcohol Abuse TherapyLaboratoriesTreatment OutcomeHealth Care Costs
Grant awards (30)
Guanfacine for women with AUD: A multisite study using a telehealth approach$704,592
R01 · FY2025 · AA · contact PI
Combined guanfacine and mindfulness meditation as an adjunct to buprenorphine maintenance in OUD$390,895
R61 · FY2025 · DA
Guanfacine for women with AUD: A multisite study using a telehealth approach$731,258
R01 · FY2024 · AA · contact PI
Combined guanfacine and mindfulness meditation as an adjunct to buprenorphine maintenance in OUD$421,621
R61 · FY2024 · DA
Dexamethasone to target stress and immune system changes during early abstinence in individuals with Alcohol Use Disorder (AUD)$189,406
R21 · FY2022 · AA · contact PI
Dexamethasone to target stress and immune system changes during early abstinence in individuals with Alcohol Use Disorder (AUD)$229,281
R21 · FY2021 · AA · contact PI
Cognitive targets for medications development in early abstinent alcoholics$128,693
K02 · FY2020 · AA · contact PI
Cognitive targets for medications development in early abstinent alcoholics$128,693
K02 · FY2019 · AA · contact PI
Guanfacine to reduce relapse risk in women with alcohol use disorder (AUD)$228,682
R21 · FY2018 · AA · contact PI
Cognitive targets for medications development in early abstinent alcoholics$128,693
K02 · FY2018 · AA · contact PI
Guanfacine to reduce relapse risk in women with alcohol use disorder (AUD)$187,823
R21 · FY2017 · AA · contact PI
Cognitive targets for medications development in early abstinent alcoholics$128,693
K02 · FY2017 · AA · contact PI
Effect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol Relapse$473,601
R01 · FY2016 · AA
Cognitive targets for medications development in early abstinent alcoholics$128,693
K02 · FY2016 · AA · contact PI
Effect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol Relapse$576,053
R01 · FY2015 · AA
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk$343,198
R01 · FY2015 · AA
Effect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol Relapse$552,007
R01 · FY2014 · AA
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk$343,198
R01 · FY2014 · AA · contact PI
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome Incoca$156,220
K01 · FY2014 · DA · contact PI
Stress system changes in alcoholics with and without depressive symptomatology$68,821
R03 · FY2014 · AA · contact PI
Effect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol Relapse$529,244
R01 · FY2013 · AA
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk$329,046
R01 · FY2013 · AA · contact PI
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome Incoca$156,220
K01 · FY2013 · DA · contact PI
Stress system changes in alcoholics with and without depressive symptomatology$70,950
R03 · FY2013 · AA · contact PI
Effect of Prazosin on Alcohol Craving, Stress Dysregulation and Alcohol Relapse$544,751
R01 · FY2012 · AA
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk$352,750
R01 · FY2012 · AA · contact PI
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome Incoca$156,220
K01 · FY2012 · DA · contact PI
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk$351,688
R01 · FY2011 · AA · contact PI
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome Incoca$149,277
K01 · FY2011 · DA · contact PI
Cognitive Processes for Pharmacotherapy Development and Treatment Outcome Incoca$153,720
K01 · FY2010 · DA · contact PI